These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25388532)

  • 1. Editorial: (Thematic Issue: medicinal chemistry of Farnesoid X Receptor (FXR) modulators: the-state-of-the-art).
    Marinozzi M
    Curr Top Med Chem; 2014; 14(19):2127-8. PubMed ID: 25388532
    [No Abstract]   [Full Text] [Related]  

  • 2. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.
    Merk D; Steinhilber D; Schubert-Zsilavecz M
    Future Med Chem; 2012 May; 4(8):1015-36. PubMed ID: 22650242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists.
    Lamers C; Schubert-Zsilavecz M; Merk D
    Curr Top Med Chem; 2014; 14(19):2188-205. PubMed ID: 25388533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators.
    Schierle S; Schmidt J; Kaiser A; Merk D
    ChemMedChem; 2018 Dec; 13(23):2530-2545. PubMed ID: 30353976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current advances in therapeutic applications of nuclear receptors.
    Fiorucci S
    Curr Top Med Chem; 2012; 12(6):484-5. PubMed ID: 22242851
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
    Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
    Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
    Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M
    J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment.
    Fiorucci S; Mencarelli A; Distrutti E; Palladino G; Cipriani S
    Curr Med Chem; 2010; 17(2):139-59. PubMed ID: 19941473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and optimization of benzimidazole derivatives as a novel chemotype of farnesoid X receptor (FXR) antagonists.
    Teno N; Iguchi Y; Yamashita Y; Mori N; Une M; Nishimaki-Mogami T; Gohda K
    Bioorg Med Chem; 2017 Mar; 25(6):1787-1794. PubMed ID: 28190654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in the ligands and their complex structures of farnesoid X receptor].
    Li WH; Fu J; Zheng MY; Liu GX; Tang Y
    Yao Xue Xue Bao; 2012 Jun; 47(6):704-15. PubMed ID: 22919716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
    Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
    Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FXR: a promising target for the metabolic syndrome?
    Cariou B; Staels B
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice.
    Liu X; Guo GL; Kong B; Hilburn DB; Hubchak SC; Park S; LeCuyer B; Hsieh A; Wang L; Fang D; Green RM
    Hepatology; 2018 Jul; 68(1):304-316. PubMed ID: 29377207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).
    Flatt B; Martin R; Wang TL; Mahaney P; Murphy B; Gu XH; Foster P; Li J; Pircher P; Petrowski M; Schulman I; Westin S; Wrobel J; Yan G; Bischoff E; Daige C; Mohan R
    J Med Chem; 2009 Feb; 52(4):904-7. PubMed ID: 19159286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
    Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
    Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
    Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells.
    Kainuma M; Takada I; Makishima M; Sano K
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29958417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders.
    Fiorucci S; Zampella A; Distrutti E
    Curr Top Med Chem; 2012; 12(6):605-24. PubMed ID: 22242859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.